IL2RB interleukin 2 receptor subunit beta
ENSG00000100385 · protein coding · Open Targets profile
Receptor for interleukin-2. This beta subunit is involved in receptor mediated endocytosis and transduces the mitogenic signals of IL2. Probably in association with IL15RA, involved in the stimulation of neutrophil phagocytosis by IL15 (PubMed:15123770, PubMed:31040185). {ECO:0000269|PubMed:15123770, ECO:0000269|PubMed:31040184, ECO:0000269|PubMed:31040185}.
Each band is a group of drugs. It runs from the kind of drug on the left to the furthest stage that drug has reached in any disease on the right. Thicker bands mean more drugs.
Approved bands are highlighted. Withdrawn means the drug was pulled from the market or from development. A combined phase counts as the later one (Phase 1/2 is shown as Phase 2). Hover a band for the drug names. Source: Open Targets Platform, fetched live.
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Small molecule
- Structure with Ligand
- Antibody
- Phase 1 Clinical, UniProt loc high conf, GO CC high conf, UniProt SigP or TMHMM
- PROTAC
- Half-life Data
- Other modalities
- Approved Drug
gnomAD loss of function constraint: o/e 0.3844499886035919 (upper bound 0.5766699910163879). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 209 registry trials, updated in the last three years, of the most advanced drugs against IL2RB (nogapendekin alfa inbakicept, aldesleukin, basiliximab, denileukin diftitox, simlukafusp alfa, pegenzileukin, recombinant human interleukin-15), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- Steven A RosenbergNational Cancer Institute (NCI) · 4 of 5 trials Phase 2+
- James C YangNational Cancer Institute (NCI) · 4 of 4 trials Phase 2+Ph1/Ph2NCT03190941 · Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patientsbrief
- Udai S KammulaUPMC Hillman Cancer Center · 3 of 3 trials Phase 2+
- Christian S HinrichsRutgers Cancer Institute · 2 of 3 trials Phase 2+
- Rodabe N AmariaM.D. Anderson Cancer Center · 2 of 3 trials Phase 2+
- Amir A JazaeriM.D. Anderson Cancer Center · 2 of 2 trials Phase 2+
- Emil LouDivision of Hematology, Oncology and Transplantation, University of Minnesota · 2 of 2 trials Phase 2+
- Jayson GarmizoAssociate Director, Clinical Operations · 2 of 2 trials Phase 2+
- Kenneth NewellEmory University · 2 of 2 trials Phase 2+
- Rodolphe THIEBAUTUniversity Hospital, Bordeaux · 2 of 2 trials Phase 2+Ph4NCT02328963 · Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection When Treated With an Immunosuppressive Regimen Including Everolimus and Reduced Dose of Cyclosporine Versus an Immunosuppressive Regimen With Mycophenolic Acid and Standard Dose of Cyclosporine Abrief
- Stephanie L GoffNational Cancer Institute (NCI) · 2 of 2 trials Phase 2+
- Amod SarnaikH. Lee Moffitt Cancer Center and Research Institute · 1 of 4 trials Phase 2+
- Scott M NorbergNational Cancer Institute (NCI) · 1 of 2 trials Phase 2+
- sharmila koppisettiCelularity Incorporated · 1 of 2 trials Phase 2+
- Adi DiabM.D. Anderson Cancer Center · 1 of 1 trials Phase 2+
Registry trials of nogapendekin alfa inbakicept, aldesleukin, basiliximab, denileukin diftitox, simlukafusp alfa, pegenzileukin, recombinant human interleukin-15 updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 168 of 196 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. 13 trials list no sites and are left out. Source: ClinicalTrials.gov, fetched live.
179 trials of drugs against IL2RB were stopped early; 27 give no reason
Terminated, withdrawn and suspended interventional trials of nogapendekin alfa inbakicept, aldesleukin, basiliximab, denileukin diftitox, simlukafusp alfa, pegenzileukin, recombinant human interleukin-15, humik-beta-1, mik-beta-1, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 25 most recent of 179.
- terminated · 2026-11-09 · Alaunos Therapeutics · Aldesleukin (IL-2)“Sponsor halted enrollment on 14 Aug 2023 for business reasons after a Board review of funding needs and permanently discontinued TCR-T cell manufacturing. The study was not stopped for safety reasons.”
- terminated · 2026-09-24 · National Institute of Allergy and Infectious Diseases (NIAID) · Basiliximab“Secondary to safety concerns plus change in Campath® (alemtuzumab) availability.”
- terminated · 2026-09-24 · National Institute of Allergy and Infectious Diseases (NIAID) · basiliximab“Safety: Stopping rule not met.”
- terminated · 2026-09-01 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · matched by the registry's drug synonyms“In light of the impending acquisition of the project partner, Shanghai Bintie Biotechnology Co., Ltd., the company has resolved to close all IT centers and discontinue the clinical research project.”
- withdrawn · 2026-08-28 · ImmunityBio, Inc. · Nogapendekin Alfa Inbakicept (N803)“The sponsor has changed the development plans which is not for safety reasons.”
- terminated · 2026-07-30 · ImCheck Therapeutics, an Ipsen company · matched by the registry's drug synonyms“The study was terminated based on sponsor decision unrelated to safety or efficacy. The study met the key primary and secondary endpoints, however two patients were receiving treatment at the decision point, preventing protocol-defined completion.”
- suspended · 2026-07-14 · David Wald · matched by the registry's drug synonyms“Drugs unavailable”
- withdrawn · 2026-06-22 · ImmunityBio, Inc. · Drug: Nogapendekin alfa inbakicept (NAI)“Sponsor decision”
- withdrawn · 2026-06-08 · Celularity Incorporated · matched by the registry's drug synonyms“No participants were enrolled. Study was withdrawn prior to treatment initiation.”
- terminated · 2026-05-26 · ImmunityBio, Inc. · Nogapendekin alfa inbakicept (NAI) + Nivolumab + Ipilimumab + Carboplatin + Nab-paclitaxel“There are no longer active subjects on QUILT-2.023. Data will be entered into clinicaltrials.gov within 1 year of the primary completion date.”
- terminated · 2026-05-22 · University Hospital, Bordeaux · matched by the registry's drug synonyms“target number of inclusion not reached”
- terminated · 2026-05-19 · National Cancer Institute (NCI) · Aldesleukin“Study was closed due to lack of accrual and study outcomes overlapped with another protocol's eligibility.”
- terminated · 2026-05-15 · Iovance Biotherapeutics, Inc. · matched by the registry's drug synonyms“After reviewing the available safety and efficacy data to date, Iovance concluded that the study reached the required number of events for evaluation of study endpoints.”
- withdrawn · 2026-05-08 · ImmunityBio, Inc. · Nogapendekin alfa inbakicept (NAI)“New protocol developed”
- withdrawn · 2026-05-08 · ImmunityBio, Inc. · matched by the registry's drug synonyms“New protocol developed”
- terminated · 2026-03-16 · Radboud University Medical Center · matched by the registry's drug synonyms“Stop funding”
- withdrawn · 2026-02-23 · Intima Bioscience, Inc. · Aldesleukin“No recruitment”
- terminated · 2026-01-23 · National Cancer Institute (NCI) · Aldesleukin“Study was terminated due to poor accrual.”
- withdrawn · 2026-01-15 · Camillo Ricordi and Jay Skyler · matched by the registry's drug synonyms“Study withdrawn prior to enrollment due to funding issues”
- terminated · 2025-12-24 · Sanofi · matched by the registry's drug synonyms“Early discontinuation based on strategic sponsor decision not driven by any safety concerns”
- withdrawn · 2025-12-24 · City of Hope Medical Center · Aldesleukin“no resource”
- terminated · 2025-12-15 · Synthorx, Inc, a Sanofi company · matched by the registry's drug synonyms“The study was terminated as per Sponsor decision. The decision was not related to any safety concerns.”
- terminated · 2025-12-08 · University of Washington · Aldesleukin“Insufficient funding”
- terminated · 2025-12-02 · National Cancer Institute (NCI) · IL-2 (Aldesleukin)“Site plans to become a site for a multicenter study of this therapy”
- terminated · 2025-11-10 · University of Southern California · Induction Immunosuppression with Basiliximab or Rabbit Anti Thymoglobulin (rATG)“Research contract expired”
Paediatric incentives and obligations for IL2RB's drugs
For nogapendekin alfa inbakicept, aldesleukin, basiliximab, denileukin diftitox, simlukafusp alfa, pegenzileukin, recombinant human interleukin-15, humik-beta-1, mik-beta-1: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: no · IL2RB is not on the listRule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: yes · EMEA-001556-PIP02-24 (aldesleukin, Treatment of amyotrophic lateral sclerosis): W: decision granting a waiver in all age groups for all conditions or indications, 13 Sept 2024Rule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA EMEA-001556-PIP02-24, 2026-11-11
- EU orphan designation: yes · EU/3/22/2578 positive 24 Feb 2022: Treatment of amyotrophic lateral sclerosis; EU/3/01/075 positive 11 Dec 2001: Treatment of cutaneous T-cell lymphoma; EU/3/03/146 withdrawn 30 Jun 2003: Treatment of renal-cell carcinomaRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: yes · Anktiva: authorised since 16 Feb 2026, conditional; Simulect: authorised since 9 Oct 1998Rule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA data download (dated snapshot), 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of nogapendekin alfa inbakicept, aldesleukin, basiliximab, denileukin diftitox, simlukafusp alfa, pegenzileukin, recombinant human interleukin-15, humik-beta-1, mik-beta-1Rule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-11
- Registered studies open to children: yes · 141 interventional studies of nogapendekin alfa inbakicept, aldesleukin, basiliximab, denileukin diftitox, simlukafusp alfa, pegenzileukin, recombinant human interleukin-15, humik-beta-1, mik-beta-1 include patients under 18; 11 are recruiting, not yet recruiting or activeRule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-11
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 10 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.